RP2 Injection for Oral Leukoplakia
(INTERCEPT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called RP2, an injected immune therapy made from a modified virus, to determine its safety in treating early warning signs of mouth cancer. The goal is to prevent oral precancer conditions from developing into full-blown cancer. The trial seeks individuals diagnosed with certain high-risk oral conditions, such as leukoplakia or erythroplakia, which indicate potential changes in the mouth that could lead to cancer. Participants should have at least one measurable lesion (a patch or sore) in their mouth that can be tracked throughout the study. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.
Do I have to stop taking my current medications for the trial?
The trial does not specify if you need to stop taking your current medications, but you cannot use certain antivirals like acyclovir or valacyclovir. If you are on long-term corticosteroids, the dose must not exceed prednisone 20 mg daily.
Is there any evidence suggesting that RP2 is likely to be safe for humans?
Research has shown that RP2, a genetically modified herpes simplex virus, has been tested in humans and has a good safety record. In earlier studies, RP2 did not cause severe side effects that halted the study, allowing the treatment to be administered without major issues.
RP2 has been tested for its tumor-fighting ability, and similar treatments have been well-tolerated. However, RP2 is still under investigation for safety and effectiveness in treating early-stage oral cancer conditions. While early results are promising, further research is necessary to confirm that RP2 is safe and effective for all patients.12345Why do researchers think this study treatment might be promising?
RP2 is unique because it offers a novel approach to treating oral leukoplakia by using a specialized injection directly targeting the affected oral mucosa. Unlike traditional treatments, such as surgical removal or laser therapy, RP2 works by potentially harnessing the body's immune response to address the abnormal cells more directly and effectively. Researchers are excited about RP2 because it could provide a less invasive option with potentially fewer side effects and a more targeted action, which might improve patient outcomes and comfort compared to existing treatments.
What evidence suggests that RP2 might be an effective treatment for oral leukoplakia?
Research has shown that RP2, a modified herpes virus, could be a promising cancer treatment. In earlier studies, RP2 shrank or eliminated tumors by enhancing the body's immune response against cancer cells. It contains GM-CSF, a protein that boosts the immune system, and an anti-CTLA-4 antibody, which helps the immune system better identify and attack cancer cells. In this trial, participants will receive RP2 injections to evaluate its potential as a treatment for oral precancers and possibly prevent them from turning into cancer.12678
Who Is on the Research Team?
Glenn J. Hanna, MD
Principal Investigator
Dana-Farber Cancer Institute
Are You a Good Fit for This Trial?
This trial is for individuals with oral leukoplakia, a condition that can lead to mouth cancer. Participants should be at high risk of their condition progressing to cancer but have not yet developed it.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive RP2 injections every 2 weeks with in-clinic visits and assessments
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- RP2
Trial Overview
The study tests the safety and potential effectiveness of RP2 injections, which is a modified herpes virus aimed at preventing oral precancerous conditions from becoming cancerous.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Enrolled participants will complete the following: * A 3 subject safety run-in will be conducted with participants enrollment staggered. If \> 1 subject experiences a grade 4-5 adverse event (AE), study enrollment will pause for review by PI and study sponsor. If there are 0 grade 4-5 AEs, enrollment will proceed. * Baseline in-clinic visit with assessments, oral mucosal punch biopsy, and RP2 injection (week 1). * In-clinic visits on weeks 3, 5, 7, 8, 9, 11, 13, 15, and 16. * RP2 injections on weeks 1, 3, 5, 7, 9, 11, 13, and 15. * Repeat oral mucosal punch biopsy at week 8. * Follow up: every 3 months for up to 2 years.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Glenn J. Hanna
Lead Sponsor
Replimune Inc.
Industry Sponsor
Published Research Related to This Trial
Citations
A Phase 2 Study of Intralesional RP2 as Immunoprevention ...
The goal of this study is to understand the safety, tolerability, and potential efficacy of an injected immune therapy called RP2 to treat oral precancer ...
A phase 1 trial of RP2, a first-in-class, enhanced potency ...
RP2 has demonstrated antitumor activity in preclinical models using viruses similar to RP2 expressing murine versions of anti-CTLA-4 and GM-CSF, both alone and ...
Oncolytic Herpes Simplex Virus Therapy: Latest Advances ...
Oncolytic virus (OV) immunotherapy, particularly with oncolytic herpes simplex virus (oHSV), has become a promising new strategy in cancer treatment.
507 A phase 1 clinical trial of RP2, an enhanced potency ...
RP2 is an enhanced-potency oncolytic HSV-1 that expresses GM-CSF, an anti-CTLA-4 antibody-like molecule, and the fusogenic gibbon ape leukemia ...
5.
onclive.com
onclive.com/view/herpes-simplex-1-oncolytic-showcases-antitumor-activity-across-heavily-pretreated-solid-tumorsHerpes Simplex-1 Oncolytic Showcases Antitumor Activity ...
Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single ...
Oncolytic virus OH2 extends survival in patients with PD-1 ...
OH2 oncolytic virotherapy exhibited a favorable safety profile without dose-limiting toxicities (DLTs) and demonstrated durable antitumor ...
7.
trial.medpath.com
trial.medpath.com/clinical-trial/7a5d02a3aa5a41a7/nct06623110-phase-2-study-intralesional-rp2-oral-precancerous-diseasePhase II Study of RP2 as Immunoprevention in High-Risk Oral ...
The goal of this study is to understand the safety, tolerability, and potential efficacy of an injected immune therapy called RP2 to treat oral precancer ...
Presage of oncolytic virotherapy for oral cancer with herpes ...
Melanoma in the oral cavity is the target of oncolytic HSV-1. Oncolytic virotherapy is a hopeful and realistic modality for the treatment of oral cancer.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.